London Breast Institute, the Princess Grace Hospital, 45 Nottingham Place, London W1U 5NY, UK.
Anticancer Res. 2013 May;33(5):2179-83.
Inhibitors of DNA binding (ID) are known to have a role in embryogenesis and oncogenesis. In this study, we analyzed the role of ID1 and ID2 in breast cancer, by assessing associations of mRNA expression with clinicopathological parameters.
Breast cancer tissues (n=152) and adjacent normal tissues (n=31) underwent reverse transcription and quantitative- polymerase chain reaction (qPCR). Transcript levels were correlated with clinicopathological data.
Patients who were disease-free had significantly lower ID1 mRNA expression than all other patients (p=0.0033). Higher expression was associated with worse disease-free (p=0.001) and overall survival (p=0.02). ID2 expression was directly associated with the Nottingham Prognostic Index (NPI) (NPI 2 vs. 3; p=0.0062) and worsening clinical outcome (disease-free vs. mortality: p=0.0004), and with worse disease-free (p=0.01) and overall survival (p=0.005).
Our findings are suggestive of a role for ID1 and ID2 in human breast cancer as possible prognostic markers and therapeutic targets meriting further validating investigations, by immunohistochemistry and mechanistic studies.
已知 DNA 结合抑制剂 (ID) 在胚胎发生和肿瘤发生中起作用。在这项研究中，我们通过评估 mRNA 表达与临床病理参数的关联，分析了 ID1 和 ID2 在乳腺癌中的作用。
对 152 例乳腺癌组织和 31 例相邻正常组织进行逆转录和定量聚合酶链反应 (qPCR)。将转录水平与临床病理数据相关联。
无病患者的 ID1 mRNA 表达明显低于所有其他患者（p=0.0033）。高表达与无病（p=0.001）和总生存（p=0.02）不良相关。ID2 表达与诺丁汉预后指数 (NPI) 直接相关（NPI 2 与 3 相比；p=0.0062），与临床结局恶化（无病与死亡率相比：p=0.0004）相关，与无病（p=0.01）和总生存（p=0.005）不良相关。
我们的研究结果表明，ID1 和 ID2 在人类乳腺癌中可能作为预后标志物和治疗靶点发挥作用，值得进一步通过免疫组织化学和机制研究进行验证。
